Skip to main content
SpringerLink
Log in

Lipid Association Increases the Potency Against Primary Medulloblastoma Cells and Systemic Exposure of l-(2-Chloroethyl)-3-Cyclohexyl-1-Nitrosourea (CCNU) in Rats

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. To reduce the systemic toxicity and prolong the systemic presence of l-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea (CCNU), a lipid-based drug carrier was designed and characterized.

Methods. The degree of CCNU association with lipid vesicles composed of 1,2-dimyristoyl-sn- glycero-3-phosphocholine (DMPC) and l,2-dimyristoyl-sn-glycero-3-phosphoglycerol (DMPG) (1:1, m/m) was characterized and the drug decomposition rates of lipid-drug complexes were monitored. Effects of lipid association on drug potency against medulloblastoma cells and total systemic drug exposure in rats were determined.

Results. At a CCNU:lipid molar ratio greater than 1:5, more than 90% of the drug was associated with the lipid vesicles. In aqueous suspensions, lipid association significantly reduced the first-order drug decomposition rate. In addition, lipid-associated CCNU exhibited a 4-fold increase in drug sensitivity with medulloblastoma cells. IC50 values for CCNU admixed and encapsulated with lipid vesicles were 18 ± 4.9 and 14.0 ± 2.2 μM, respectively, compared to 83 ± 11.0 μM for free CCNU. When administered to rats, lipid-associated CCNU increased the AUC (area under the concentration-time curve) of CCNU by approximately 2-fold (20.46 ± 2.15 compared to 39.59 ±1.87 μg⋅min/ml), and the terminal half-life (t1/2β) by almost 9-fold (17 ± 9 compared to 147 ± 48 min) over free CCNU. Despite the increase in total systemic drug exposure, rats treated with lipid-associated CCNU exhibited a significantly lower frequency of acute neurotoxicity.

Conclusions. These data indicate that CCNU associated with lipid vesicles may increase drug stability, potency, and systemic exposure in rats.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. A. P. Polednak and B. S. Flannery. Brain, other central nervous system, and eye cancer. Cancer Suppl. 5:330–337 (1995).

    Google Scholar 

  2. R. J. Packer. Brain tumors in children. Curr. Opin. Pediatr. 8:549–557 (1996).

    Google Scholar 

  3. F. H. Tomlinson, B. W. Scheithauer, F. B. Meyer, W. A. Smithson, E. G. Shaw, G. M. Miller, and R. V. Groover. Medulloblastoma: I. Clinical, diagnostic, and therapeutic overview. J. Child Neurol. 7:142–155 (1992).

    Google Scholar 

  4. J. P. Provias and L. E. Becker. Cellular and molecular pathology of medulloblastoma. J. Neuro-Oncol. 29:35–43 (1996).

    Google Scholar 

  5. B. H. Cohen and R. J. Packer. Chemotherapy for medulloblastomas and primitive neuroectodermal tumors. J. Neuro-Oncol. 29:55–68 (1996).

    Google Scholar 

  6. I. J. Dunkel and J. L. Finlay. High dose chemotherapy with autologous stem cell rescue for patients with medulloblastoma. J. Neuro-Oncol. 29:69–74 (1996).

    Google Scholar 

  7. D. C. Chatterji, R. F. Green, and J. F. Gallelli. Mechanism of hydrolysis of hologenated nitrosoureas. J. Pharm. Sci. 67:1527–1532 (1978).

    Google Scholar 

  8. D. J. Reed, H. E. May, R. B. Boose, K. M. Gregory, and M. A. Beilstein. 2-Chloroethanol formation as evidence for a 2-chloroethyl alkylating intermediate during chemical degradation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea amd 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea. Cancer Res. 35:568–576 (1975).

    Google Scholar 

  9. M. J. Lind and C. Ardiet. Pharmacokinetics of alkylating agents. Cancer Surveys. 17:157–188 (1993).

    Google Scholar 

  10. T. L. Loo and R. L. Dion. Colorimetric method for the determination of 1,3-bis (2-chloroethyl)-1-nitrosourea. J. Pharm. Sci. 54:809–810 (1965).

    Google Scholar 

  11. A. C. Bratton and E. K. Marshall. A new coupling component for sulfanilamide determination. J. Biol. Chem. 128:537–54 (1939).

    Google Scholar 

  12. X. He, S. X. Skapek, C. J. Wikstrand, H. S. Friedman, J. Q. Trojanowski, J. T. Kemshead, H. B. Coakham, S. H. Bigner, and D. D. Bigner. Phenotypic analysis of four human medulloblastoma cell lines and transplantable xenografts. J. Neuropathol. Exp. Neurol. 48:48–68 (1989).

    Google Scholar 

  13. G. E. Keles, M. S. Berger, J. Srinivasan, D. D. Kolstoe, M. S. Bobola, and J. R. Silber. Establishment and characterization of four human medulloblastoma-derived cell lines. Oncol. Res. 7:493–503 (1995).

    Google Scholar 

  14. A. M. Spence and P. W. Coates. Scanning electron microscopy of cloned astrocytic lines derived from ethylnitrosourea-induced rat glioma. Virchows Arch. B Cell Pathol. 28:77–85 (1978).

    Google Scholar 

  15. S. K. Bakar and S. Niazi. Simple reliable method for chronic cannulation of the jugular vein for pharmacokinetic studies in rats. J. Pharm. Sci. 72:1027–1029 (1983).

    Google Scholar 

  16. R. G. Russo, M. T. Cattaneo, and I. Bartosek. Pharmacokinetics of nitrosoureas: comparison of 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) after oral and intravenous administration to rats. Tumori. 70:499–502 (1984).

    Google Scholar 

  17. C. Ritter and R. J. Rutman. Relative enhancement by various liposomes of BCNU effectiveness against L1210 leukemia in vivo. Res. Commun. Chem. Pathol. Pharmacol. 30:123–131 (1980).

    Google Scholar 

  18. H. Bobo, J. P. Kapp, and R. Vance. Effect of intra-arterial cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) dosage on radiographic response and regional toxicity in malignant glioma patients: proposal of a new method of intra-arterial dosage calculation. J. Neurooncol. 13:291–299 (1992).

    Google Scholar 

  19. B. A. Chabner, R. Sponzo, S. Hubbard, G. P. Canellos, R. C. Young, P. S. Schein, and V. T. Devita. High-dose intermittent intravenous infusion of procarbazine (NSC-77213). Cancer Chemother. Rep. 57:361–363 (1973).

    Google Scholar 

  20. M. Kochi, J. Kuratsu, Y. Mihara, S. Takaki, H. Seto, S. Uemura, and Y. Ushio. Ventriculolumbar perfusion of 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hyrdrochloride. Neurosurgery. 33:817–823 (1993).

    Google Scholar 

  21. M. S. Edwards, V. A. Levin, M. L. Seager, and C. B. Wilson. Intrathecal chemotherapy for leptomeningeal dissemination of medulloblastoma. Childs Brain. 8:444–451 (1981).

    Google Scholar 

  22. D. S. Fulton, V. A. Levin, P. H. Gutin, M. S. Edwards, M. L. Seager, J. Stewart, and C. B. Wilson. Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors. Cancer Chemother. Pharmacol. 8:285–291 (1982).

    Google Scholar 

  23. P. H. Gutin, H. D. Weiss, P. H. Wiernik, and M. D. Walker. Intrathecal N, N′, N″-triethylenethiophosphoramide [thio-TEPA (NSC 6396)] in the treatment of malignant meningeal disease: phase I–II study. Cancer. 38:1471–1475 (1976).

    Google Scholar 

  24. P. H. Gutin, J. A. Levi, P. H. Wiernik, and M. D. Walker. Treatment of malignant meningeal disease with intrathecal thioTepa: a phase II study. Cancer Treat. Rep. 61:885–887 (1977).

    Google Scholar 

  25. R. J. Weinkam, A. Finn, V. A. Levin, and J. P. Kane. Lipophilic drugs and lipoproteins: partitioning effects on chloroethylnitrosourea reaction rates in serum. J. Pharmacol. Exp. Ther. 214:318–323 (1980).

    Google Scholar 

  26. National Cancer Institute. Cancer screen data for NSC 79037 (CCNU). IC50 for NSC 79037 [online data; cited 1997 Aug 22]; 1(1):[8 screens]. Available from URL: http://epnwsl.ncifcrf.-gov:2345/dis3d/drugs/main/79037.html

  27. I. Kitamura, M. Kochi, Y. Matsumoto, R. Ueoka, J. Kuratsu, and Y. Ushio. Intrathecal Chemotherapy with 1,3-bis(2-chloroethyl)-1-nitrosourea encapsulated into hybrid liposomes for meningeal gliomatosis: an experimental study. Cancer Res. 56:3986–3992 (1996).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, University of Washington, Seattle, Washington, 98195

    Claudette Bethune, Aleksander Blum & Rodney J. Y. Ho

  2. Department of Pediatric Hematology and Oncology, University of Washington, Seattle, Washington, 98195

    J. Russell Geyer

  3. Department of Neurological Surgery, University of Washington, Seattle, Washington, 98195

    John R. Silber

Authors
  1. Claudette Bethune
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aleksander Blum
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Russell Geyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John R. Silber
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rodney J. Y. Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rodney J. Y. Ho.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bethune, C., Blum, A., Geyer, J.R. et al. Lipid Association Increases the Potency Against Primary Medulloblastoma Cells and Systemic Exposure of l-(2-Chloroethyl)-3-Cyclohexyl-1-Nitrosourea (CCNU) in Rats. Pharm Res 16, 896–903 (1999). https://doi.org/10.1023/A:1018886321917

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1018886321917

Search

Navigation